IRCT20211008052695N1
Recruiting
Phase 3
Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Parkinson disease.
- Sponsor
- Ahvaz University of Medical Sciences
- Enrollment
- 32
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Diagnosis of Parkinson's disease based on examination and history 2\) Patients with stage 2\-4 of Hoehn and yahr scale; 3\) Normal tests (vitamin B12, thyroid, liver, and kidney tests) 4\) Levodopa treatment for at least 3 months before the study 5\) Ability to walk at least 20 steps without the use of assistive devices
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Study of therapeutic effects of Atomoxtein in reducing the symptoms of patients with recurrent vasovagal syncopeIRCT20180125038507N1Tehran University of Medical Sciences50
Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
Not yet recruiting
Phase 3
Atomoxetine for cognitive impairment in Behcet's diseaseIRCT20211206053288N1Tehran University of Medical Sciences40
Active, not recruiting
Phase 1
Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.EUCTR2019-004455-36-FRCHU DE POITIERS45
Active, not recruiting
Not Applicable
An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions - NDChild or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHDMedDRA version: 6.1Level: PTClassification code 10003736EUCTR2005-005701-32-ITELI LILLY300